Every 10-Q that Core Laboratories Inc. (CLB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CLB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLB filings page.
Core Laboratories Inc. generated revenue of $124,609 thousand for the quarter ended June 30, 2026, down 4% from the prior-year period. Services contributed $94,277 thousand and product sales $30,332 thousand. Operating income declined to $9,151 thousand, and net income attributable to the company fell to $5,956 thousand, or diluted EPS of $0.13.
For the first six months of 2026, revenue was $246,406 thousand and net income attributable to Core Laboratories was $5,167 thousand. Net cash provided by operating activities totaled $11,774 thousand, while capital expenditures were $10,659 thousand. Long-term debt stood at $116,375 thousand with a leverage ratio of 1.30 and interest coverage of 6.53; the current ratio was 2.12:1, and available borrowing capacity under the credit facility was approximately $85.6 million.
Management highlights ongoing geopolitical conflicts in the Middle East and Russia–Ukraine region, noting a 15% to 20% reduction in global cargo movement of crude oil and derived products in the second quarter of 2026 versus a year earlier, which is reducing demand for certain laboratory assay services, though large international projects are described as more resilient.
Core Laboratories Inc. reported weaker results for the quarter ended March 31, 2026, posting total revenue of $121.8 million, down 1% from a year ago and 12% from the prior quarter. Service revenue was $94.3 million and product sales were $27.5 million.
The company recorded an operating income of $1.9 million, sharply below $4.4 million a year earlier and $15.8 million in the prior quarter, reflecting lower activity, especially in international markets affected by Middle East and Russia/Ukraine conflicts, and higher costs. Net loss attributable to Core Lab was $0.8 million compared with a small loss a year ago and profit of $4.9 million in the previous quarter.
Operating cash flow was $4.0 million and free cash flow $0.5 million after $3.4 million of operating capital expenditures. Cash stood at $22.8 million, and gross long-term debt was $117.0 million, with a leverage ratio of 1.20 and interest coverage of 7.20 under its credit facility covenants. The company repurchased 51,781 shares for about $4.0 million and paid a quarterly dividend of $0.01 per share while remaining in compliance with all debt covenants.
Core Laboratories (CLB) reported steady Q3 results. Revenue was $134.5 million, essentially flat year over year, while net income attributable to the company rose to $14.2 million, up 21%. Diluted EPS was $0.30 versus $0.25 a year ago. Services grew modestly to $101.1 million as international crude‑assay and diagnostics offset softer U.S. activity. Product sales declined to $33.4 million on weaker U.S. onshore completions.
Operating income improved to $20.9 million, aided by cost efficiencies and lower interest expense. Other income included a final insurance recovery gain of about $5.2 million related to the Aberdeen facility. Cash was $25.6 million; long‑term debt was $117.0 million gross. On July 22, the company entered a $150.0 million amended credit facility, with about $131.9 million of borrowing capacity available at quarter‑end. The board declared a $0.01 dividend on October 22, 2025. Year to date, CLB repurchased 831,478 shares for $9.8 million. After quarter‑end, CLB acquired Solintec in Brazil for an initial $2.3 million plus up to $3.7 million contingent, bolstering Reservoir Description.